GlassScriptPhysician profile
Ravi A Patel
NPI 1962667790
$10,380.60
in general payments reported to CMS, 2019-2025
50 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $776 · 2021: $972 · 2022: $1,497 · 2023: $2,080 · 2024: $1,794 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,944 · Education: $80.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.97 |
| Education | $80.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $984.78 | 2021-2024 | Superion Indirect Decompression System, Fixate |
| Novartis Pharmaceuticals Corporation | $953.61 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $940.71 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $832.27 | 2019-2025 | |
| Ucb, INC. | $733.41 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Vertiflex, INC. | $571.25 | 2019 | |
| Biogen, INC. | $515.74 | 2019-2025 | Vumerity, Tysabri |
| Supernus Pharmaceuticals, INC. | $416.24 | 2019-2021 | |
| Allergan, INC. | $413.20 | 2019-2022 | |
| Amgen INC. | $405.17 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $392.53 | 2019-2025 | Mavenclad |
| Medtronic USA, INC. | $351.21 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $339.17 | 2020-2025 | Hyqvia |
| Pfizer INC. | $255.59 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $251.40 | 2020-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $179.06 | 2023-2025 | Gocovri, Apokyn, Gocovri |
| Sk Life Science, INC. | $139.84 | 2021-2025 | |
| Microvention, INC. | $133.42 | 2019 | |
| Csl Behring | $119.25 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $114.04 | 2020-2025 | Austedo Xr |
| Lilly USA, LLC | $108.41 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $100.00 | 2019-2023 | |
| Vanda Pharmaceuticals INC. | $99.76 | 2024-2025 | Ponvory |
| Argenx US, INC. | $91.24 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Livanova USA, INC. | $84.52 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $77.79 | 2019-2024 | Gamunex-C |
| Sumitomo Pharma America, INC. | $74.60 | 2024 | Aptiom |
| Lundbeck LLC | $72.94 | 2019-2024 | Vyepti |
| Catalyst Pharmaceuticals, INC. | $70.21 | 2024 | |
| Celgene Corporation | $63.69 | 2022-2024 | Zeposia |
| Neurocrine Biosciences, INC. | $62.76 | 2019-2020 | |
| Kyowa Kirin, INC. | $40.82 | 2020-2024 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $38.00 | 2022 | |
| Acadia Pharmaceuticals INC | $35.49 | 2023-2024 | Daybue, Nuplazid |
| Sunovion Pharmaceuticals INC. | $34.23 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.77 | 2021 | |
| Neurelis, INC. | $26.94 | 2021 | |
| Ge Healthcare | $25.60 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.37 | 2024 | Purified Cortrophin Gel |
| Acorda Therapeutics, INC | $23.22 | 2022 | |
| Arbor Pharmaceuticals, INC. | $22.66 | 2022 | |
| Horizon Therapeutics Plc | $19.65 | 2023 | Uplizna |
| Medtronic, INC. | $18.65 | 2021 | |
| Tanabe Pharma America, INC. | $18.60 | 2022 | |
| Neuropace, INC. | $17.99 | 2024 | |
| Abbott Laboratories | $17.95 | 2020 | |
| Cardinal Health 200 LLC | $16.15 | 2019 | |
| Genzyme Corporation | $13.01 | 2021 | |
| Assertio Therapeutics, INC. | $11.03 | 2020 | |
| Travere Therapeutics, INC. | $1.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.